Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

STOP SPREAD BAD BUGS STOP SPREAD BAD BUGS: novel antimicrobial approaches to combat multidrug resistance in bacteria

Coordinator
Erasmus Universitair Medisch Centrum Rotterdam, Netherlands
Runs
1 September 2022 to 31 August 2027
Status
Running
EU funding
€4.0m
Total cost
—
Partners
28 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101073263

What the project is doing

In the project's own words, from its summary on CORDIS.

STOP SPREAD BAD BUGS is a new multi-disciplinary research/training consortium built to combat the alarming problem of global antimicrobial resistance. Multi-drug resistance (MDR) in bacteria is becoming increasingly common thus urgently calling for alternative approaches to develop and implement novel antibiotics. We envision a definitive solution that will require a paradigm shift. Its foundation shall be the training of a new generation of future 15 Early Stage Researchers (ESRs) by world-renowned experts in the field of drug development, infectiology, immunology and pharmacology.

A unique state-of the-art teaching/training pipeline shall be developed across 7 academic and 5 SME partners with complementary expertise in the development and testing of novel approaches to antimicrobial therapy in humans. We shall establish knowledge and expertise on carbohydrate and protein chemistry for the discovery of new drug candidates, while characterizing the underlying mechanism of existing compounds for treatment of microbial infections.

Computational modelling shall optimize the interactions of the novel entities with selected pathogens. A range of infection models allows partners to simultaneously determine compound efficacy in pre-clinical settings and investigate the potential effects of the novel antimicrobials on host tissues. State-of-the-art imaging tools will be applied to track the bacteria and novel compounds in these test systems. Uniquely, the pipeline will also determine the pharmacokinetics, and the effects of compounds on host microbiota and host immunity.

Understanding the mechanisms of action of the novel antimicrobials shall provide insights into new antimicrobial mechanisms, which may be further exploited in spin-off projects. This approach means that the STOP SPREAD BAD BUGS consortium will deliver uniquely trained, multi- and interdisciplinary ESRs that will take the continuing fight against global MDR safely into the future.

Topics

Who is involved

OrganisationCityCountryRole
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsCoordinator
Medizinische Universitaet WienWienAustriaAssociatedpartner
Tissuegnostics GmbHWienAustriaParticipant
AnitomAartselaarBelgiumParticipant
Aquilon Pharmaceuticals SAViseBelgiumParticipant
InbioseZwijnaardeBelgiumParticipant
Nutrition SciencesDrongenBelgiumParticipant
Universite De LiegeLiegeBelgiumAssociatedpartner
Universiteit GentGentBelgiumAssociatedpartner
Hylomorph AGZurichSwitzerlandParticipant
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eVMunchenGermanyAssociatedpartner
Medres-Medical Research GmbHKolnGermanyParticipant
Philipps Universitaet MarburgMarburgGermanyParticipant
Progredum GmbHKaiserslauternGermanyAssociatedpartner
Institut De Recerca I Tecnologia AgroalimentariesCaldes De Montbui BarcelonaSpainParticipant
Universitat Autonoma De BarcelonaCerdanyola Del VallesSpainAssociatedpartner
The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near DublinDublinIrelandParticipant
Associazione TourismNemiItalyAssociatedpartner
Fondazione Istituto Italiano Di TecnologiaGenovaItalyParticipant
Setlance SRLSienaItalyParticipant
Universita Degli Studi Di SienaSienaItalyAssociatedpartner
Innoso BV's-Gravenhage (Den Haag)NetherlandsAssociatedpartner
Universiteit UtrechtUtrechtNetherlandsParticipant
Universitetet I StavangerStavangerNorwayParticipant
Chemprecise Consultoria Biotecnologia Produtos Farmaceuticos E Imobiliario LdaTorres VedrasPortugalParticipant
Des Solutio - Solucoes E Consultoria Cientifica LdaCharneca De CaparicaPortugalAssociatedpartner
Faculdade de Farmácia da Universidade de LisboaLisboaPortugalAssociatedpartner
University of GlasgowGlasgowUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI